HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (`Moleculin` or the `Company`), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate, WP1122, which it believes may present a new approach to treating highly glycolytic tumors like pancreatic cancer and glioblastoma. `WP1122 represents an opportunity to attack the metabolism of cancer by exploiting the Warburg principle, which explains that some tumors are highly dependent on glycolysis, a specific metabolism of glucose, for growth and survival,` commented Walter Klemp, Moleculin`s...
|
